Last reviewed · How we verify
CD40 agonist monoclonal antibody CP-870,893 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
CD40 agonist monoclonal antibody CP-870,893 (CD40 agonist monoclonal antibody CP-870,893) — Abramson Cancer Center at Penn Medicine.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CD40 agonist monoclonal antibody CP-870,893 TARGET | CD40 agonist monoclonal antibody CP-870,893 | Abramson Cancer Center at Penn Medicine | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CD40 agonist monoclonal antibody CP-870,893 CI watch — RSS
- CD40 agonist monoclonal antibody CP-870,893 CI watch — Atom
- CD40 agonist monoclonal antibody CP-870,893 CI watch — JSON
- CD40 agonist monoclonal antibody CP-870,893 alone — RSS
Cite this brief
Drug Landscape (2026). CD40 agonist monoclonal antibody CP-870,893 — Competitive Intelligence Brief. https://druglandscape.com/ci/cd40-agonist-monoclonal-antibody-cp-870-893. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab